First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastomaLinda M. Liau, Santosh Kesari, Keyoumars Ashkan et al.|Journal of Translational Medicine|2018Cited by 540
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal MelanomaRichard D. Carvajal, Gary K. Schwartz, Mark R. Albertini et al.|JAMA|2014Cited by 429
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent GlioblastomaLinda M. Liau, Lynne P. Taylor, Keyoumars Ashkan et al.|JAMA Oncology|2022Cited by 411
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm studyJames R. Berenson, Regina A. Swift, Ralph V. Boccia et al.|British Journal of Haematology|2006Cited by 83
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastomaLinda M. Liau, Santosh Kesari, Keyoumars Ashkan et al.|Journal of Translational Medicine|2018Cited by 17